Aerie Pharma (AERI) Misses Q4 EPS by 44c

Aerie Pharma (NASDAQ: AERI) reported Q4 EPS of ($1.21), $0.44 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $24.66 million versus the consensus estimate of $19.46 million.

2020 Guidance

Aerie currently expects full-year 2020 net revenues to be in the range of $100 to $110 million on a U.S. GAAP basis for Rhopressa® and Rocklatan® combined. Aerie also currently expects full-year 2020 net cash used in operating activities to be in the range of $110 million to $120 million, on a U.S. GAAP basis, with operating expenses in full-year 2020 remaining consistent with full-year 2019.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M